A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs RPL 554 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 07 Nov 2017 According to a Verona Pharma media release, company announced today that it has enrolled more than 200 patients in this trial and are enrolling ahead of schedule. Top-line data is expected in mid-2018.
- 27 Jul 2017 The first patients have been dosed in this trial, according to a Verona Pharma media release.
- 16 Jul 2017 Status changed from planning to recruiting.